2012
DOI: 10.1089/ten.tea.2011.0311
|View full text |Cite
|
Sign up to set email alerts
|

Selective Removal of Undifferentiated Human Embryonic Stem Cells Using Magnetic Activated Cell Sorting Followed by a Cytotoxic Antibody

Abstract: One of the most pertinent concerns of using differentiated cells derived from human embryonic stem cells (hESC) is the presence of residual undifferentiated hESC, because they carry a risk of teratoma formation. A new cell-cell separation approach that eliminates teratoma-forming hESC in order to ensure safer cell therapy was developed. By combining antibodies (IgMs or IgGs) for the selective removal of undifferentiated hESC using magnetic activated cell sorting (MACS) followed by selective killing of residual… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
42
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 66 publications
(44 citation statements)
references
References 31 publications
2
42
0
Order By: Relevance
“…An example of a cytotoxic antibody that detects and removes hESCs is the monoclonal antibody mAB-84 [17], which binds to PODXL (Podocalyxin-like protein 1) on hESCs and initiates a sequence of events that leads to hESC-membrane damage by formation of leaking pores [18]. It has been proposed that using the monoclonal antibody mAB-84 in a two-step cell-cell separation approach can eliminate teratoma-forming hESC from differentiated cell types [19]. In this strategy, an initial depletion of hESCs was achieved via MACS using a panel of commonly used hESC cell-surface markers, which was followed by selective elimination of residual undifferentiated stem cells post-MACS using the cytotoxic antibody mAB-84, an approach that appears to increase the safety of cell transplantation [19].…”
Section: How To Purge Residual Tumorigenic Pluripotent Stem Cells Fromentioning
confidence: 99%
See 1 more Smart Citation
“…An example of a cytotoxic antibody that detects and removes hESCs is the monoclonal antibody mAB-84 [17], which binds to PODXL (Podocalyxin-like protein 1) on hESCs and initiates a sequence of events that leads to hESC-membrane damage by formation of leaking pores [18]. It has been proposed that using the monoclonal antibody mAB-84 in a two-step cell-cell separation approach can eliminate teratoma-forming hESC from differentiated cell types [19]. In this strategy, an initial depletion of hESCs was achieved via MACS using a panel of commonly used hESC cell-surface markers, which was followed by selective elimination of residual undifferentiated stem cells post-MACS using the cytotoxic antibody mAB-84, an approach that appears to increase the safety of cell transplantation [19].…”
Section: How To Purge Residual Tumorigenic Pluripotent Stem Cells Fromentioning
confidence: 99%
“…It has been proposed that using the monoclonal antibody mAB-84 in a two-step cell-cell separation approach can eliminate teratoma-forming hESC from differentiated cell types [19]. In this strategy, an initial depletion of hESCs was achieved via MACS using a panel of commonly used hESC cell-surface markers, which was followed by selective elimination of residual undifferentiated stem cells post-MACS using the cytotoxic antibody mAB-84, an approach that appears to increase the safety of cell transplantation [19].…”
Section: How To Purge Residual Tumorigenic Pluripotent Stem Cells Fromentioning
confidence: 99%
“…Therefore, if the aim is to use antibodies to detect human pluripotent cells and purge them from a sample of hPSC-derived cells, selected antibodies should not also react with antigens on the specific differentiated cell types intended for transplantation. Unfortunately, there are limited numbers of antibodies that detect cell surface markers on live hPSCs surface marker is not sufficient to eliminate all hPSC, suggesting that any attempt to eliminate all hPSC pluripotent subpopulations should rely on methods that use two or more antibodies detecting different epitopes expressed by hPSCs [9][10] . As mentioned above, only hPSC-derived cells that could be determined as pluripotent stem cell-free cell populations are appropriate for human transplantation.…”
Section: Introductionmentioning
confidence: 99%
“…6,7 Similarly, magnetic-activated cell sorter (MACS) uses magnetic. 8,9 Alternatively, label-free cell separation methods have exploited inherent a) J. Song and M. Song contributed equally to this work.…”
mentioning
confidence: 99%